Abstract
Background
Canavan disease is a rare leukodystrophy with no current treatment. rAAVβASPA has been developed for gene delivery to the central nervous system (CNS) for Canavan disease. This study represents the first use of a viral vector in an attempt to ameliorate a neurodegenerative disorder.
Methods
Subjects received intracranial infusions via six cranial burr holes. Adenoβassociated virus, serotype 2 (AAV2), mediated intraparenchymal delivery of the human aspartoacylase cDNA at a maximum dose of 1 Γ 10^12^ vector genomes per subject. The immune response and safety profiles were monitored in the followβup of ten subjects.
Results
Following rAAV2 administration, we found no evidence of AAV2 neutralizing antibody titers in serum for the majority of subjects tested (7/10). In a subset (3/10) of subjects, low to moderately high levels of AAV2 neutralizing antibody with respect to baseline were detected. In all subjects, there were minimal systemic signs of inflammation or immune stimulation. In subjects with catheter access to the brain lateral ventricle, cerebrospinal fluid was examined and there was a complete absence of neutralizing antibody titers with no overt signs of brain inflammation.
Conclusions
rAAV2 vector administration to the human CNS appears well tolerated. The low levels of immune response to AAV2 detected in 3/10 subjects in this study suggest at this dose and with intraparenchymal administration this approach is relatively safe. Longβterm monitoring of subjects and expansion to phase II/III will be necessary in order to make definitive statements on safety and efficacy. Copyright Β© 2006 John Wiley & Sons, Ltd.